A Phase 3 interventional study of REGN5713 and REGN5714 in Allergic Rhinitis and Conjunctivitis, sponsored by Regeneron Pharmaceuticals. Completed at 37 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-27.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 141 studies in Rhinitis, Allergic with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. Rhinitis, Allergic · United States.
Among the 141 studies in Rhinitis, Allergic with a site in United States, this one is the 27th largest by enrollment of the 119 interventional ones that give a count, is one of 5 that started in 2021, is one of 33 in phase 3, and was the 133rd registered.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
Browse Rhinitis, Allergic studies →5 of the 141 studies in Rhinitis, Allergic with a site in United States are open now. Recruiting first, the newest first:
Polyrizon Ltd. · Sites in United States
Ages 18–75
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 3–100
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 18–60 · Healthy volunteers
QHSLab, Inc. · Sites in United States
Ages 4–100 · Healthy volunteers
QHSLab, Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
141 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 23 · Phase 3 35 · Phase 4 25
First in 1996; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 353 is above the median of 68 across 552 interventional studies indexed under Rhinitis, Allergic.
Median enrollment 54 across the 119 interventional studies, 60 across the 21 observational. Of the 122 that completed or were terminated, 58 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 141 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 3 studies filed under Rhinitis, Allergic — fewer than ten, so there is no comparison to draw.
3 of the studies in Rhinitis, Allergic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06623799QHSLab, Inc.Impact of Help-Seeking Behaviors on Allergic Rhinitis and Mental Health: A Longitudinal Study | 2027-01-25 |
| NCT05331170The University of Texas Medical Branch, GalvestonViral Mucosal Reprogramming | 2027-05-01 |
| NCT07588672Polyrizon Ltd.Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis | 2027-07-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 141 studies in Rhinitis, Allergic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.
Key Inclusion Criteria
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
REGN5713-5714-5715 administered subcutaneously
Drug: REGN5713 · Drug: REGN5714 · Drug: REGN5715
Placebo matching REGN5713-5714-5715 administered subcutaneously
Drug: Placebo
Combined Symptom and Medication Score (CSMS) in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo
The average CSMS will be calculated based on daily symptom score and daily medication score recorded over the duration of the birch pollen season (BPS). CSMS is calculated by adding the Daily Medication Score (DMS) and Total Symptom Score (TSS) together, with scores ranging between 0 (none) and 38 (severe).
Time frame: Until the end of Birch Pollen Season, up to Week 16
Total Symptom Score (TSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo
TSS is a combined score of TOSS and TNSS. TNSS and TOSS are scored as in part 1 each for a combined TSS of 0 (none) to 18 (severe)
Time frame: Until the end of Birch Pollen Season, up to Week 16
Total Nasal Symptom Score (TNSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo
Total nasal symptom score (TNSS) is from 0 to 12 and is based on assessment of 4 nasal symptoms graded on a Likert scale ranging from 0 (none) to 3 (severe) for congestion, itching, and rhinorrhea, and from 0 (none) to 3 (5 or more sneezes) for sneezing.
Time frame: Until the end of Birch Pollen Season, up to Week 16
Total Ocular Symptom Score (TOSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo
Total ocular symptom score is 0 to 6 and is based on itching/redness/gritty feeling and tearing/watering; each of the 2 symptoms is graded 0 (absent), 1 (mild), 2 (moderate), and 3 (severe)
Time frame: Until the end of Birch Pollen Season, up to Week 16
Daily Medication Score (DMS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo
The Daily Medication Score (DMS) is calculated by adding points for each pre-specified medication taken as follows: desloratadine 5 mg 6 points/dose; maximum daily score 6 points, olopatadine 1 mg/mL each drop 1.5 points/drop; maximum daily score 6 points, mometasone furoate 50 ug/dose 2.0 points/spray; maximum daily score 8 points). The scale is 0 (minimum) to 20 (maximum)
Time frame: Until the end of Birch Pollen Season, up to Week 16
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Throughout the Study
Number of participants with any Treatment Emergent Adverse Events (TEAEs) from participating in study
Time frame: Up to Day 127
Number of Participants With Serious TEAEs Throughout the Study
Number of participants with any Serious Treatment Emergent Adverse Events (TEAEs) from participating in study
Time frame: Up to Day 127
Change From Baseline to the End of Study in Birch SPT Mean Wheal Diameter in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo
Number of participants who showed change from baseline to the end of the study in Birch Skin Prick Test (SPT) Mean Wheal Diameter, in participants who received REGN5713-5714-5715 compared to placebo
Time frame: Baseline through Day 127
Percent Change From Baseline to the End of Study in Birch SPT Mean Wheal Diameter in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo
Time frame: Baseline through Day 127
Serum Concentration of REGN5713 Over the Study Duration
Time frame: Day 0, Day 56, Day 112
Serum Concentration of REGN5714 Over the Study Duration
Time frame: Up to Day 127
Serum Concentration of REGN5715 Over the Study Duration
Time frame: Up to Day 127
Percentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5713 Throughout the Study
Percentage of participants who developed antibodies to intervention provided during study
Time frame: Up to Day 127
Percentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5714 Throughout the Study
Percentage of participants who developed antibodies to intervention provided during study
Time frame: Up to Day 127
Percentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5715 Throughout the Study
Percentage of participants who developed antibodies to intervention provided during study
Time frame: Up to Day 127
Number of "Well Days"
"Well Days" are defined as days when rescue medication is not utilized and the Total symptom score (TSS) is ≤2/18
Time frame: Until the end of Birch Pollen Season, up to Week 16
| Milestone | REGN5713-5714-5715 | Placebo Only |
|---|---|---|
| Started | 176 | 177 |
| Completed | 166 | 172 |
| Not completed | 10 | 5 |
| Withdrew: Withdrawal by subject | 6 | 2 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
The average CSMS will be calculated based on daily symptom score and daily medication score recorded over the duration of the birch pollen season (BPS). CSMS is calculated by adding the Daily Medication Score (DMS) and Total Symptom Score (TSS) together, with scores ranging between 0 (none) and 38 (severe).
| Scores on a Scale | REGN5713-5714-5715 | Placebo Only |
|---|---|---|
| Combined Symptom and Medication Score (CSMS) in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo | 7.503 ± 0.6545 | 8.498 ± 0.6534 |
TSS is a combined score of TOSS and TNSS. TNSS and TOSS are scored as in part 1 each for a combined TSS of 0 (none) to 18 (severe)
| Scores on a Scale | REGN5713-5714-5715 | Placebo Only |
|---|---|---|
| Total Symptom Score (TSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo | 5.19 ± 0.397 | 5.62 ± 0.396 |
Total nasal symptom score (TNSS) is from 0 to 12 and is based on assessment of 4 nasal symptoms graded on a Likert scale ranging from 0 (none) to 3 (severe) for congestion, itching, and rhinorrhea, and from 0 (none) to 3 (5 or more sneezes) for sneezing.
| Score on a scale | REGN5713-5714-5715 | Placebo Only |
|---|---|---|
| Total Nasal Symptom Score (TNSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo | 3.76 ± 0.278 | 4.00 ± 0.277 |
Total ocular symptom score is 0 to 6 and is based on itching/redness/gritty feeling and tearing/watering; each of the 2 symptoms is graded 0 (absent), 1 (mild), 2 (moderate), and 3 (severe)
| Score on a scale | REGN5713-5714-5715 | Placebo Only |
|---|---|---|
| Total Ocular Symptom Score (TOSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo | 1.43 ± 0.150 | 1.62 ± 0.150 |
The Daily Medication Score (DMS) is calculated by adding points for each pre-specified medication taken as follows: desloratadine 5 mg 6 points/dose; maximum daily score 6 points, olopatadine 1 mg/mL each drop 1.5 points/drop; maximum daily score 6 points, mometasone furoate 50 ug/dose 2.0 points/spray; maximum daily score 8 points). The scale is 0 (minimum) to 20 (maximum)
| Score on a Scale | REGN5713-5714-5715 | Placebo Only |
|---|---|---|
| Daily Medication Score (DMS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo | 2.316 ± 0.3993 | 2.882 ± 0.3986 |
Number of participants with any Treatment Emergent Adverse Events (TEAEs) from participating in study
| Count of Participants | REGN5713-5714-5715 | Placebo Only |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Throughout the Study | 92 | 85 |
Number of participants with any Serious Treatment Emergent Adverse Events (TEAEs) from participating in study
| Count of Participants | REGN5713-5714-5715 | Placebo Only |
|---|---|---|
| Number of Participants With Serious TEAEs Throughout the Study | 3 | 0 |
Number of participants who showed change from baseline to the end of the study in Birch Skin Prick Test (SPT) Mean Wheal Diameter, in participants who received REGN5713-5714-5715 compared to placebo
| millimeters | REGN5713-5714-5715 | Placebo Only |
|---|---|---|
| Change From Baseline to the End of Study in Birch SPT Mean Wheal Diameter in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo | -3.139 ± 0.5086 | 0.553 ± 0.5067 |
| Percentage | REGN5713-5714-5715 | Placebo Only |
|---|---|---|
| Percent Change From Baseline to the End of Study in Birch SPT Mean Wheal Diameter in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo | -26.38 ± 5.179 | 8.17 ± 5.160 |
| mg/L | REGN5713-5714-5715 |
|---|---|
| Day 0 | 0 ± 0 |
| Day 56 | 10.0 ± 3.97 |
| Day 112 | 2.53 ± 1.57 |
| mg/L | REGN5713-5714-5715 |
|---|---|
| Day 0 | 0 ± 0 |
| Day 56 | 14.7 ± 4.68 |
| Day 112 | 4.82 ± 2.16 |
| mg/L | REGN5713-5714-5715 |
|---|---|
| Day 0 | 0 ± 0 |
| Day 56 | 16.6 ± 5.34 |
| Day 112 | 5.34 ± 2.35 |
Percentage of participants who developed antibodies to intervention provided during study
| Percentage of Participants | REGN5713-5714-5715 | Placebo Only |
|---|---|---|
| Percentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5713 Throughout the Study | 0 | 0 |
Percentage of participants who developed antibodies to intervention provided during study
| Percentage of Participants | REGN5713-5714-5715 | Placebo Only |
|---|---|---|
| Percentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5714 Throughout the Study | 0 | 0 |
Percentage of participants who developed antibodies to intervention provided during study
| Percentage of Participants | REGN5713-5714-5715 | Placebo Only |
|---|---|---|
| Percentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5715 Throughout the Study | 0 | 0 |
"Well Days" are defined as days when rescue medication is not utilized and the Total symptom score (TSS) is ≤2/18
| Days | REGN5713-5714-5715 | Placebo Only |
|---|---|---|
| Number of "Well Days" | 8.3 ± 1.42 | 8.6 ± 1.42 |
Collected over 28 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/176 (0%) | 0/176 (0%) | 43/176 (24.4%) |
| R5713-5714-5715 900 mg | 0/173 (0%) | 3/173 (1.7%) | 32/173 (18.5%) |
| Event | Placebo | R5713-5714-5715 900 mg |
|---|---|---|
| AppendicitisInfections and infestations | 0/176 | 1/173 |
| Thermal burnInjury, poisoning and procedural complications | 0/176 | 1/173 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/176 | 1/173 |
| Event | Placebo | R5713-5714-5715 900 mg |
|---|---|---|
| Vaccination complicationInjury, poisoning and procedural complications | 22/176 | 17/173 |
| HeadacheNervous system disorders | 19/176 | 15/173 |
| NasopharyngitisInfections and infestations | 9/176 | 5/173 |
| Age, Continuous(years) | REGN5713-5714-5715 | Placebo Only | Total |
|---|---|---|---|
| Mean | 39.6 ± 14.15 | 42.1 ± 14.36 | 40.9 ± 14.29 |
| Sex: Female, Male(Participants) | REGN5713-5714-5715 | Placebo Only | Total |
|---|---|---|---|
| Female | 102 | 102 | 204 |
| Male | 74 | 75 | 149 |
| Ethnicity (NIH/OMB)(Participants) | REGN5713-5714-5715 | Placebo Only | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 4 |
| Not Hispanic or Latino | 172 | 174 | 346 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | REGN5713-5714-5715 | Placebo Only | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 3 | 10 | 13 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 1 | 2 | 3 |
| White | 165 | 161 | 326 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 3 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Data sharing details ↗ · vivli.org
Ran from Jan 2021 to primary completion in Aug 2021, 7 months.
Results were first posted in Oct 2022, 1 year 2 months after primary completion.
Of 31 industry-sponsored phase 3 interventional studies under Rhinitis, Allergic, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 41. This study's 7 months is below that.
Counting every sponsor, half of 41 studies reached it within 13 months; a quarter within 6 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bremzalerbart · Atisnolerbart